Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL ISIN · CA57384M1077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 255 across all filing types
Latest filing 2026-05-20 Remuneration Information
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Remuneration Information Classification · 75% confidence The document is a corporate news release announcing the award of deferred share units (DSUs) to independent directors in lieu of cash fees, including vesting terms and settlement details. This is directly related to director compensation arrangements rather than a broader regulatory report or share transaction. Under the specified taxonomy, this falls under “Remuneration Information” (Report detailing compensation for top executives and directors, Code: DEF 14A).
2026-05-20 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 84% confidence The document is a Canadian securities regulatory form (“Form 45-106F1 Report of Exempt Distribution”) used to report details of an exempt distribution under National Instrument 45-106. It is neither a financial report (10-K, IR, ER, MDA), nor a meeting/management announcement, but a compliance filing under securities regulation. This fits the general fallback category of Regulatory Filings (RNS).
2026-04-27 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 72% confidence The document is a Canadian securities regulatory form (Form 45-106F1) used to report an exempt distribution under National Instrument 45-106. It is a statutory filing rather than an annual report, earnings release, or investor presentation. It does not announce a meeting result or management change. It therefore falls into the general regulatory filings category (fallback).
2026-04-27 English
Report of exempt distribution (45-106F1).pdf
Capital/Financing Update Classification · 85% confidence The document is Form 45-106F1 “Report of Exempt Distribution,” a mandatory regulatory filing in Canada that details an exempt distribution of securities (convertible debentures) raising capital. It is not an annual or quarterly report, earnings release, or AGM material, but specifically reports on a financing transaction. This falls under “Capital/Financing Update” (CAP).
2026-04-27 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 85% confidence The document is a Canadian securities regulatory Form 45-106F1 “Report of Exempt Distribution,” which is a mandatory compliance filing reporting the details of a private securities distribution. This is not an Annual Report (10-K), earnings release, capital markets announcement, or other specific corporate disclosure category. It is a miscellaneous regulatory filing submitted to SEDAR+ that does not match any of the narrowly defined types, so it falls under the fallback category “Regulatory Filings” (RNS).
2026-04-27 English
News release - English.pdf
Investor Presentation Classification · 80% confidence The document is a corporate press release announcing Marvel Biosciences Corp.’s upcoming participation and presentation at a neuroscience partnering and licensing summit. It does not contain financial results, quorum or voting information, share transactions, or regulatory forms. It is not an earnings release or annual/interim report but is clearly directed at investors and stakeholders to promote the company’s strategy and pipeline at an investor-focused event. This aligns with the definition of Investor Presentation (IP).
2026-04-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.